- Home
- IBG vs DTIL Comparison
IBG vs DTIL Comparison
Compare IBG & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- DTIL
- Stock Information
- Founded
- IBG 2018
- DTIL 2006
- Country
- IBG Australia
- DTIL United States
- Employees
- IBG N/A
- DTIL N/A
- Industry
- IBG Beverages (Production/Distribution)
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- DTIL Health Care
- Exchange
- IBG Nasdaq
- DTIL Nasdaq
- Market Cap
- IBG 75.7M
- DTIL 81.4M
- IPO Year
- IBG 2024
- DTIL 2019
- Fundamental
- Price
- IBG $1.75
- DTIL $5.22
- Analyst Decision
- IBG Strong Buy
- DTIL Strong Buy
- Analyst Count
- IBG 1
- DTIL 2
- Target Price
- IBG N/A
- DTIL $47.00
- AVG Volume (30 Days)
- IBG 122.9K
- DTIL 246.2K
- Earning Date
- IBG 11-28-2025
- DTIL 11-03-2025
- Dividend Yield
- IBG N/A
- DTIL N/A
- EPS Growth
- IBG N/A
- DTIL N/A
- EPS
- IBG N/A
- DTIL N/A
- Revenue
- IBG $2,931,243.00
- DTIL $698,000.00
- Revenue This Year
- IBG N/A
- DTIL N/A
- Revenue Next Year
- IBG N/A
- DTIL $135.19
- P/E Ratio
- IBG N/A
- DTIL N/A
- Revenue Growth
- IBG N/A
- DTIL N/A
- 52 Week Low
- IBG $1.48
- DTIL $3.61
- 52 Week High
- IBG $9.85
- DTIL $8.82
- Technical
- Relative Strength Index (RSI)
- IBG 32.21
- DTIL 33.14
- Support Level
- IBG $1.68
- DTIL $5.67
- Resistance Level
- IBG $1.94
- DTIL $6.46
- Average True Range (ATR)
- IBG 0.30
- DTIL 0.59
- MACD
- IBG -0.15
- DTIL -0.27
- Stochastic Oscillator
- IBG 3.50
- DTIL 3.23
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.